Nada Nabil Saad

Nada Nabil Saad

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Nada Nabil Saad has a total of 8 co-authors. Here are the top co-authors by number of shared publications:

  • Abanoub Sherif

    Medical and Pharmaceutical Industrial Biotechnology Department, College of Biotechnology, Misr University for Science and Technology (MUST), 6th of October City, Giza 12566, Egypt

    1 shared publication
  • Ahmed Bakr

    Industrial Pharmacy Department, College of Pharmaceutical Sciences and Drug Manufacturing, Misr University for Science and Technology (MUST), 6th of October City, Giza 12566, Egypt

    1 shared publication
  • Alamer Ata

    Medical and Pharmaceutical Industrial Biotechnology Department, College of Biotechnology, Misr University for Science and Technology (MUST), 6th of October City 12566, Giza, Egypt

    1 shared publication
  • Malak Nasr Elkady

    Department of Biotechnology, Faculty of Biotechnology, Misr University for Science and Technology, 6th of October City, Giza 12566, Egypt

    1 shared publication
  • Maria Tamer

    Medical and Pharmaceutical Industrial Biotechnology Department, College of Biotechnology, Misr University for Science and Technology (MUST), 6th of October City 12566, Giza, Egypt

    1 shared publication
  • Rehab Abdelmonem

    Industrial Pharmacy Department, College of Pharmaceutical Sciences and Drug Manufacturing, Misr University for Science and Technology (MUST), 6th of October City, Giza 12566, Egypt

    1 shared publication

Latest Publications

  • Open Access

    Tailored Therapeutic Strategies for Fetuses, Neonates, Pediatrics, Geriatrics, Athletes, and Critical Cases in the Era of Personalized Medicine

    by Ahmed Bakr, Youssef Basem, Abanoub Sherif, Alamer Ata, Nada Nabil Saad, Yassmin Emarh Fayed, Maria Tamer, Malak Nasr Elkady, Rehab Abdelmonem

    Precision medicine, which relies on genomic, multi-omic, phenotypic, and environmental data, has the potential to transform healthcare from population-focused heuristics to individualized prevention, diagnosis, and treatment. Moreover, recent advances in sequencing, molecular profiles, wearable sensors, and machine learning have created opportunities for rapid translational innovation: rapid genomic diagnosis in neonatal and paediatric rare diseases, targeted oncology, pharmacogenomic-based prescribing strategies, and individual sport performance. Nevertheless, the vast majority of innovations remain in centers of specialism or pilot programs, rather than routinely or equitably integrated into clinical or athletic practice. This narrative review synthesizes translational evidence across the life course—in pregnancy, paediatrics, adult medicine, geriatrics, and sportomics—to find reproducible clinical and performance examples which enable precision-based alternative approaches to management, outcome, or preparation; and to reshape those examples into pragmatic, scalable priorities which minimize inequity, and maximize benefit. We undertook a structured narrative synthesis of peer-reviewed literature, trials, clinician translation programs, implementation studies, and sportomics reports, prioritizing examples that demonstrate utility, reproducibility, and impact. Important findings suggest that multi-omics and rapid sequencing improve diagnostic yield and time to diagnosis. Molecular profiling and circulating tumor DNA help realize adaptive treatment selection. Integrated genomics, metabolomics, wearable physiology, and AI analytics facilitate individualized training, injury-risk stratification, and recovery optimization. But systematic value is limited by insufficient representative validation, dataset bias, poor interoperability, regulatory uncertainty, workforce preparedness, and inequities of access. Converting a promise into population- and performance-level value requires coordinated action across four fronts: representative validation; interoperable, privacy-preserving infrastructures; clinician- and coach-centered implementation; and templates for scalable, cost-sensitive deployment.